CNS Disorders  >>  BL-1020  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BL-1020 / BioLineRx
NCT01363349: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia

Checkmark P2/3 CLARITY data
Mar 2013 - Mar 2013: P2/3 CLARITY data
Terminated
2b
269
Europe, RoW
CYP-1020, BL-1020, Risperidone
BioLineRx, Ltd.
Schizophrenia, Cognitive Effect on Schizophrenic Patients
03/13
04/13
NCT00480571: Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

Completed
2
90
Europe, RoW
BL-1020, BL 1020 High Dose
BioLineRx, Ltd.
Schizophrenia, Schizoaffective Disorder
12/07
12/07
NCT00722176: Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

Completed
2
220
US
BL-1020, BL-1020 10-30 mg, BL-1020 High Dose, risperidone
BioLineRx, Ltd.
Schizophrenia
07/09
12/09
NCT00567710: A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

Checkmark P2 data
Oct 2012 - Oct 2012: P2 data
Checkmark P2 data
Sep 2012 - Sep 2012: P2 data
Completed
2
360
US
BL - 1020, Placebo, Risperidone
BioLineRx, Ltd.
Schizophrenia
07/09
09/09

Download Options